403 related articles for article (PubMed ID: 31899565)
1. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
Piske M; Zhou H; Min JE; Hongdilokkul N; Pearce LA; Homayra F; Socias ME; McGowan G; Nosyk B
Addiction; 2020 Aug; 115(8):1482-1493. PubMed ID: 31899565
[TBL] [Abstract][Full Text] [Related]
2. Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
Krebs E; Homayra F; Min JE; MacDonald S; Gold L; Carter C; Nosyk B
Drug Alcohol Depend; 2021 Aug; 225():108799. PubMed ID: 34087747
[TBL] [Abstract][Full Text] [Related]
3. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.
Socías ME; Wood E; Kerr T; Nolan S; Hayashi K; Nosova E; Montaner J; Milloy MJ
Drug Alcohol Depend; 2018 Aug; 189():90-95. PubMed ID: 29894910
[TBL] [Abstract][Full Text] [Related]
4. Opioid agonist treatment uptake within provincial correctional facilities in British Columbia, Canada.
Kurz M; Dale LM; Min JE; Hongdilokkul N; Greiner L; Olley M; McLeod KE; Slaunwhite A; Nosyk B
Addiction; 2022 May; 117(5):1353-1362. PubMed ID: 34729848
[TBL] [Abstract][Full Text] [Related]
5. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.
Pearce LA; Min JE; Piske M; Zhou H; Homayra F; Slaunwhite A; Irvine M; McGowan G; Nosyk B
BMJ; 2020 Mar; 368():m772. PubMed ID: 32234712
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of health system performance measures for opioid use disorder in British Columbia, Canada.
Nosyk B; Min JE; Pearce LA; Zhou H; Homayra F; Wang L; Piske M; McCarty D; Gardner G; O'Briain W; Wood E; Daly P; Walsh T; Henry B
Drug Alcohol Depend; 2022 Apr; 233():109375. PubMed ID: 35231716
[TBL] [Abstract][Full Text] [Related]
7. Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada.
Kurz M; Min JE; Dale LM; Nosyk B
J Subst Abuse Treat; 2022 Feb; 133():108647. PubMed ID: 34740484
[TBL] [Abstract][Full Text] [Related]
8. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
Socías ME; Wood E; Lake S; Nolan S; Fairbairn N; Hayashi K; Shulha HP; Liu S; Kerr T; Milloy MJ
Addiction; 2018 Dec; 113(12):2250-2258. PubMed ID: 30238568
[TBL] [Abstract][Full Text] [Related]
9. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
10. Determinants of selection into buprenorphine/naloxone among people initiating opioid agonist treatment in British Columbia.
Homayra F; Hongdilokkul N; Piske M; Pearce LA; Zhou H; Min JE; Krebs E; Nosyk B
Drug Alcohol Depend; 2020 Feb; 207():107798. PubMed ID: 31927163
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, Canada: A retrospective cohort study.
Kennedy MC; Crabtree A; Nolan S; Mok WY; Cui Z; Chong M; Slaunwhite A; Ti L
PLoS Med; 2022 Dec; 19(12):e1004123. PubMed ID: 36454732
[TBL] [Abstract][Full Text] [Related]
12. Opioid agonist therapy and mortality among First Nations and other residents with concurrent alcohol use disorder in British Columbia, Canada: A population-based cohort study.
Barker B; Min JE; Homayra F; Piske M; Sabeti S; Meilleur L; Nosyk B; Wieman N
Drug Alcohol Depend; 2023 Sep; 250():110908. PubMed ID: 37544037
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Paul LA; Bayoumi AM; Chen C; Kocovska E; Smith BT; Raboud JM; Gomes T; Kendall C; Rosella LC; Bitonti-Bengert L; Rush B; Yu M; Spithoff S; Crichlow F; Wright A; Watford J; Besharah J; Munro C; Taha S; Nosyk B; Strike C; Manson H; Kahan M; Leece P
Addiction; 2023 Apr; 118(4):686-697. PubMed ID: 36401610
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada.
Piske M; Thomson T; Krebs E; Hongdilokkul N; Bruneau J; Greenland S; Gustafson P; Karim ME; McCandless LC; Maclure M; Platt RW; Siebert U; Socías ME; Tsui JI; Wood E; Nosyk B
BMJ Open; 2020 Sep; 10(9):e036102. PubMed ID: 32912944
[TBL] [Abstract][Full Text] [Related]
15. The cascade of care for opioid use disorder among youth in British Columbia, 2018.
Krebs E; Min JE; Zhou H; Davison C; McGowan G; Nosyk B
J Subst Abuse Treat; 2021 Nov; 130():108404. PubMed ID: 34118696
[TBL] [Abstract][Full Text] [Related]
16. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
17. Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.
Weicker SA; Hayashi K; Grant C; Milloy MJ; Wood E; Kerr T
Drug Alcohol Depend; 2019 Dec; 205():107672. PubMed ID: 31706251
[TBL] [Abstract][Full Text] [Related]
18. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
Larney S; Jones NR; Hickman M; Nielsen S; Ali R; Degenhardt L
Addiction; 2023 Aug; 118(8):1527-1539. PubMed ID: 36843415
[TBL] [Abstract][Full Text] [Related]
19. Incremental expenditures attributable to daily dispensation and witnessed ingestion for opioid agonist treatment in British Columbia: 2014-20.
Nosyk B; Kurz M; Guerra-Alejos BC; Piske M; Dale L; Min JE
Addiction; 2023 Jul; 118(7):1376-1380. PubMed ID: 36772838
[TBL] [Abstract][Full Text] [Related]
20. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
